{"denoms":[{"counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"}],"units":"Participants"}],"description":"Reduction in pituitary tumor volume by over 50% as assessed by MRI to measurements made at baseline.","groups":[{"description":"Patients receive 4 mg oral rosiglitazone maleate once daily in week 1 and then 8 mg once daily beginning in week 2 and continuing for up to 6 months in the absence of disease progression or unacceptable toxicity.\n\nrosiglitazone maleate : Given orally","id":"OG000","title":"Group 1 (ACTH-secreting Adenomas)"},{"description":"Patients receive 4 mg oral rosiglitazone maleate once daily in week 1 and then 8 mg once daily beginning in week 2 and continuing for up to 12 months in the absence of disease progression or unacceptable toxicity.\n\nrosiglitazone maleate : Given orally","id":"OG001","title":"Group 2 (Non-secreting Macroadenomas)"}],"populationDescription":"No data was analyzed for this outcome measure as there was insufficient data to perform analysis.","reportingStatus":"POSTED","timeFrame":"12 months","title":"Efficacy of Rosiglitazone Maleate on Cushing Disease","type":"PRIMARY"}